|
|
Induction in younger patient?Induction in younger patient?a. What is your preferred induction treatment for an otherwise healthy 62-year-old transplant-eligible patient with standard-risk multiple myeloma (MM) and normal renal function? b. Assuming you determine that the patient (age 62, normal renal function) had “high-risk” disease, what induction treatment would you offer?
Chng WJ et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia 2014;28(2):269-77. Abstract Jakubowiak AJ et al. Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up. Proc ASCO 2013;Abstract 8543. Mikhael JR et al. Management of newly diagnosed symptomatic multiple myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc 2013;88(4):360-76. Abstract Reeder CB et al. Long-term survival with CyBorD induction therapy in newly diagnosed multiple myeloma. Proc ASH 2013;Abstract 3192. Richardson PG et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010;116(5):679-86. Abstract Rosiñol L et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: A randomized phase 3 PETHEMA/GEM study. Blood 2012;120(8):1589-96. Abstract |